X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.globenewswire.com/news-release/2024/04/02/2855618/0/en/HUTCHMED-and-Innovent-Jointly-Announce-NDA-Acceptance-in-China-for-Fruquintinib-Combination-with-Sintilimab-for-the-Treatment-of-Advanced-Endometrial-Cancer-with-Priority-Review-St.html
https://www.globenewswire.com//news-release/2024/02/07/2824809/0/en/HUTCHMED-Highlights-Presentation-of-Phase-III-Data-on-Fruquintinib-in-Second-Line-Gastric-Cancer-at-ASCO-Plenary-Series-Session.html
https://www.globenewswire.com/news-release/2024/01/30/2819569/0/en/HUTCHMED-Receives-ELUNATE-fruquintinib-Marketing-Approval-in-Hong-Kong-for-Treatment-of-Metastatic-Colorectal-Cancer.html
https://www.globenewswire.com//news-release/2023/12/13/2795215/0/en/HUTCHMED-Announces-Continued-Inclusion-of-ELUNATE-fruquintinib-and-SULANDA-surufatinib-in-the-National-Reimbursement-Drug-List-in-China-at-Current-Terms.html
https://www.globenewswire.com//news-release/2023/12/13/2795176/0/en/HUTCHMED-Announces-that-it-has-Completed-Enrollment-of-a-Phase-II-III-Trial-of-Fruquintinib-in-Combination-with-Sintilimab-for-Advanced-Renal-Cell-Carcinoma-in-China.html
https://www.yicaiglobal.com/news/fruquintinib-becomes-first-shanghai-made-antineoplastic-drug-to-be-prescribed-in-us
https://www.takeda.com/newsroom/newsreleases/2023/Takeda-Receives-US-FDA-Approval-of-FRUZAQLA-fruquintinib-for-Previously-Treated-Metastatic-Colorectal-Cancer/
https://www.globenewswire.com/news-release/2023/07/20/2707823/0/en/HUTCHMED-Receives-Breakthrough-Therapy-Designation-in-China-for-Fruquintinib-Combination-with-Sintilimab-for-Treatment-of-Advanced-Endometrial-Cancer-and-Completes-Enrollment-of-Re.html
https://www.takeda.com/newsroom/newsreleases/2023/takeda-and-hutchmed-announce-publication-of-phase-3-fresco-2-results/
https://www.globenewswire.com/news-release/2023/05/25/2676813/0/en/Takeda-and-HUTCHMED-Announce-New-Drug-Application-NDA-for-Fruquintinib-for-Treatment-of-Previously-Treated-Metastatic-Colorectal-Cancer-Granted-Priority-Review.html
https://www.globenewswire.com/news-release/2023/04/18/2648545/0/en/HUTCHMED-Announces-NDA-Acceptance-in-China-for-Fruquintinib-in-Second-Line-Gastric-Cancer.html
https://www.fiercepharma.com/pharma/takeda-makes-113m-deal-hutchmed-cancer-drug-fruquintinib
https://www.globenewswire.com/news-release/2022/12/19/2576023/0/en/HUTCHMED-Initiates-Rolling-Submission-of-NDA-to-U-S-FDA-for-Fruquintinib-for-the-Treatment-of-Refractory-Colorectal-Cancer.html
https://www.fiercepharma.com/pharma/chinas-hutchmed-posts-positive-data-frutiga-gastric-cancer
https://www.globenewswire.com/news-release/2022/10/27/2542692/0/en/HUTCHMED-Initiates-a-Phase-II-III-Trial-of-Fruquintinib-in-Combination-with-Sintilimab-for-Advanced-Renal-Cell-Carcinoma-in-China.html
https://www.globenewswire.com/news-release/2022/08/08/2493507/0/en/HUTCHMED-Announces-that-Fruquintinib-Global-Phase-III-FRESCO-2-Study-Has-Met-Its-Primary-Endpoint-in-Metastatic-Colorectal-Cancer.html
http://www.pharmafile.com/news/609117/elunate-receives-commercial-approval-macau
https://www.globenewswire.com/news-release/2022/01/19/2368960/0/en/HUTCHMED-Highlights-Fruquintinib-Clinical-Data-to-be-Presented-at-the-2022-ASCO-Gastrointestinal-Cancers-Symposium.html
https://www.globenewswire.com/news-release/2021/12/06/2346166/0/en/HUTCHMED-Completes-Planned-Enrollment-of-FRESCO-2-a-Global-Phase-III-Trial-of-Fruquintinib-in-Metastatic-Colorectal-Cancer.html
https://www.globenewswire.com/news-release/2020/09/04/2088898/0/en/Chi-Med-Initiates-FRESCO-2-a-Global-Phase-III-Trial-of-Fruquintinib-in-Metastatic-Colorectal-Cancer.html
https://www.chi-med.com/chi-med-highlights-clinical-data-to-be-presented-at-the-upcoming-esmo-virtual-congress-2020/
https://www.chi-med.com/chi-med-and-lilly-to-collaborate-in-commercializing-elunate-in-china/
https://www.prnewswire.com/news-releases/innovent-and-chi-med-expand-global-collaboration-to-evaluate-the-combination-of-sintilimab-and-surufatinib-in-solid-tumors-300936292.html
https://endpts.com/chi-med-cuts-surufatinib-phiii-short-fda-greenlights-herceptin-copycat-from-amgen-allergan/
https://endpts.com/oncology-dominates-a-cambrian-explosion-in-chinas-drug-pipeline-as-mckinsey-guru-bets-on-a-burst-of-innovation/
http://www.pmlive.com/pharma_news/chi-med_and_lillys_cancer_drug_elunate_a_milestone_for_china_1263760
https://www.fiercepharma.com/pharma-asia/despite-recent-historic-win-lilly-partner-chi-med-s-elunate-fails-lung-cancer
https://endpts.com/eli-lilly-partner-chi-med-sees-shares-tank-as-its-newly-approved-cancer-drug-flunks-phiii-lung-cancer-trial/
https://www.forbes.com/sites/johnlamattina/2018/09/13/can-a-cancer-drug-originated-in-china-be-a-success-in-the-u-s/#60a9a8e2dd54
https://www.reuters.com/article/us-chi-med-cancer-china/boost-for-made-in-china-medicine-as-chi-med-wins-key-approval-idUSKCN1LL0NA?feedType=RSS&feedName=healthNews
Market Place
Share 
